Cholesterol and cholesterol-rich membranes in prostate cancer: An update

Tumori

Volumn 94, Issue 5, 2008, Pages 633-639

  Di Vizio, Dolores ^a   Solomon, Keith R ^a   Freeman, Michael R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Caveolae; Cholesterol; Detergent resistant microdomains (DRM); Prostate cancer

Indexed keywords

CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLEASON SCORE; HUMAN; INTERNALIZATION; LIPID RAFT; LIPOPROTEIN METABOLISM; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN VARIANT; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

EID: 47849097390     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400501     Document Type: Review

References (63)

1. Cook LS, Goldoft M, Schwartz SM, Weiss NS: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol, 161(1): 152-155, 1999.
2. Fleshner N, Bagnell PS, Klotz L, Venkateswaran V: Dietary fat and prostate cancer. J Urol, 171(2 Pt 2): S19-24, 2004.
3. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE: Statins and prostate cancer risk: a case-control study. Am J Epidemiol, 162(4): 318-325, 2005.
4. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ: The risk of cancer in users of statins. J Clin Oncol, 22(12): 2388-2394, 2004.
5. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sorensen HT, Olsen JH: Cancer risk among statin users: a population-based cohort study. Int J Cancer, 114(4): 643-647, 2005.
6. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM: Statins and cancer risk: a meta-analysis. JAMA, 295(1): 74-80, 2006.
7. Platz EA: Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev, 16(11): 2175-2180, 2007.
8. Siegel D, Lopez J: Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA, 278(21): 1745-1748, 1997.
9. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE: Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis, 24(3): 453-459, 2003.
10. Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov, 4(12): 977-987, 2005.
11. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7(4): 256-269, 2007.
12. Simons K, Vaz WL: Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct, 33: 269-295, 2004.
13. Freeman MR, Solomon KR: Cholesterol and prostate cancer. J Cell Biochem, 91(1): 54-69, 2004.
14. Hager MH, Solomon KR, Freeman MR: The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care, 9(4): 379-385, 2006.
15. De Stefani E, Mendilaharsu M, Deneo-Pellegrini H, Ronco A: Influence of dietary levels of fat, cholesterol, and calcium on colorectal cancer. Nutr Cancer, 29(1): 83-89, 1997.
16. Horn-Ross PL, Morrow M, Ljung BM: Diet and the risk of salivary gland cancer. Am J Epidemiol, 146(2): 171-176, 1997.
17. Jarvinen R, Knekt P, Seppanen R, Teppo L: Diet and breast cancer risk in a cohort of Finnish women. Cancer Lett, 114(1-2): 251-253, 1997.
18. Schaffner CP, Gordon HW: The hypocholesterolemic activity of orally administered polyene macrolides. Proc Natl Acad Sci U S A, 61(1): 36-41, 1968.
19. Yang G, Truong LD, Wheeler TM, Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res, 59(22): 5719-5723, 1999.
20. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M, Lisanti MP: Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem, 280(26): 25134-25145, 2005.
21. Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG, Lisanti MP: Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling, caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem, 274(47): 33551-33556, 1999.
22. Li L, Ren CH, Tahir SA, Ren C, Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol, 23(24): 9389-9404, 2003.
23. Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP: Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther, 6(8): 1263-1268, 2007.
24. Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, Demichelis F, Solomon KR, Loda M, Rubin MA, Lisanti MR Freeman MR: Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle 7: 2257-2267, 2008.
25. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR: Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res, 62(8): 2227-2231, 2002.
26. Paez J, Sellers WR: PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res, 115: 145-167, 2003.
27. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest, 115(4): 959-968, 2005.
28. Solomon KR, Mallory MA, Finberg RW: Determination of the non-ionic detergent insolubility and phosphoprotein associations of glycosylphosphatidylinositol-anchored proteins expressed on T cells. Biochem J, 334 (Pt 2): 325-333, 1998.
29. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol, 1(1): 31-39, 2000.
30. Moffett S, Brown DA, Linder ME: Lipid-dependent targeting of G proteins into rafts. J Biol Chem, 275(3): 2191-2198, 2000.
31. Freeman MR, Cinar B, Lu ML: Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab, 16(6): 273-279, 2005.
32. Mukherjee A, Arnaud L, Cooper JA: Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain. J Biol Chem, 278(42): 40806-40814, 2003.
33. Hooper NM, Turner AJ: Ectoenzymes of the kidney microvillar membrane. Differential solubilization by detergents can predict a glycosyl- phosphatidylinositol membrane anchor. Biochem J, 250(3): 865-869, 1988.
34. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science, 254(5034): 1016-1019, 1991.
35. Simons K, Ikonen E: Functional rafts in cell membranes. Nature, 387(6633): 569-572, 1997.
36. Brown DA, London E: Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol, 14: 111-136, 1998.
37. van Deurs B, Roepstorff K, Hommelgaard AM, Sandvig K: Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol, 13(2): 92-100, 2003.
38. Williams TM, Lisanti MP: The Caveolin genes: from cell biology to medicine. Ann Med, 36(8): 584-595, 2004.
39. Fang PK, Solomon KR, Zhuang L, Qi M, McKee M, Freeman MR, Yelick PC: Caveolin-1alpha and -1beta perform nonredundant roles in early vertebrate development. Am J Pathol, 169(6): 2209-2222, 2006.
40. Razani B, Lisanti MP: Two distinct caveolin-1 domains mediate the functional interaction of caveolin-1 with protein kinase A. Am J Physiol Cell Physiol, 281(4): C1241-1250, 2001.
41. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, Thompson TC: Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res, 9(10 Pt 1): 3653-3659, 2003.
42. Mouraviev V, Li L, Tahir SA, Yang G, Timme TM, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, Miles BJ, Amato RJ, Kadmon D, Thompson TC: The role of caveolin-1 in androgen insensitive prostate cancer. J Urol, 168(4 Pt 1): 1589-1596, 2002.
43. Kim J, Adam RM, Solomon KR, Freeman MR: Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology, 145(2): 613-619, 2004.
44. Simons K, van Meer G: Lipid sorting in epithelial cells. Biochemistry, 27(17): 6197-6202, 1988.
45. Varma R, Mayor S: GPI-anchored proteins are organized in submicron domains at the cell surface. Nature, 394(6695): 798-801, 1998.
46. Mukherjee S, Maxfield FR: Membrane domains. Annu Rev Cell Dev Biol, 20: 839-866, 2004.
47. Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, Solomon KR, Freeman MR: Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res, 67(13): 6238-6246, 2007.
48. Cinar B, Mukhopadhyay NK, Meng G, Freeman MR: Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem, 282(40): 29584-29593, 2007.
49. Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, Pavlova N, Rubin MA, Yelick PC, Freeman MR: The proapoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. Embo J, 26(21): 4523-4534, 2007.
50. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K, Wedel H: Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol, 86(3): 257-262, 2000.
51. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev, 16(11): 2213-2217, 2007.
52. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP Jr, Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ: Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev, 16(11): 2218-2225, 2007.
53. Murtola TJ, Tammela TL, Lahtela J, Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev, 16(11): 2226-2232, 2007.
54. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst, 98(24): 1819-1825, 2006.
55. Siperstein MD: Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res, 25(13): 1462-1468, 1984.
56. Van Aelst L, D'Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev, 11(18): 2295-2322, 1997.
57. Adamson P, Marshall CJ, Hall A, Tilbrook PA: Post-translational modifications of p21rho proteins. J Biol Chem, 267(28): 20033-20038, 1992.
58. Armstrong SA, Hannah VC, Goldstein JL, Brown MS: CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol Chem, 270(14): 7864-7868, 1995.
59. Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci, 23(10): 482-486, 2002.
60. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res, 54(20): 5474-5478, 1994.
61. Yeh S, Lin HK, Kang HY, Thin T H, Lin MF, Chang C: From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA, 96: 5458-5463, 1999.
62. Mellinghoff IK, Tran C, Sawyers CL: Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res, 62(18): 5254-5259, 2002.
63. Freeman MR: HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR? Cancer Cell, 6(5): 427-428, 2004.